fishermen-americachair.blogspot.com
The deal, first announced in gives Genzyme primary responsibility for the developmeng and commercialization of thedrug target. Genzyme is conducting two phaser 3 studies onthe Cambridge, Mass.-based Genzyme has also acquiredx from Bayer the worldwide marketing and distributiomn rights to cancer treatments, Fludara and Leukine. Genzyme now has full responsibility for marketing and selling the acquiredx oncology products and will record sales revenue in the Unitef States and more than 90 other countriesx where they are During a transition period followinvgthe closing, Genzyme and Bayer HealthCare will continue to work together to ensurre no interruption in product supply to patients or support services to The deal does not include upfront payment to Bayer, but Genzyme will make payments based on its abilityu to generate revenue, if the MS drug candidate gainws approval.
Genzyme also will make future payments for the two approvedcancer drugs, basesd upon revenue. In addition, Genzyme will acquir a new Leukine manufacturing facility upon FDA approval of the which is expectedin 2010. The revenue and earnings impacft of this transaction is includedin Genzyme’se 2009 guidance. Genzyme’s (Nasdaq: stock was trading at $60.04 a share in morningf trading Tuesday, up from the previous day’ s close of $59.41.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment